Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Florida | OTHER |
Not provided
Not provided
Not provided
Not provided
This study evaluates acupuncture for the treatment of vulvodynia; specifically if it reduces vulvar pain and pain with intercourse. It also examines how long the effect of acupuncture lasts in women with vulvodynia. Half of the women will receive acupuncture and the other half will receive placebo acupuncture. Women who get a reduction in pain will monitor there pain once a week for up to 12 weeks to see how long the acupuncture effect lasts.
The investigators' goal is to demonstrate the effects of acupuncture for the treatment of vulvodynia. Up to 14 million American women have vulvodynia, a debilitating pain syndrome characterized by pain (burning, irritation, stinging or rawness) in the vulva and dyspareunia that renders sexual intercourse virtually impossible and leaves these women desperate for relief. Not only are women in pain, but they often lose their partners or have relationship difficulties due to their inability to have sexual intercourse. No therapies have been proven efficacious and rapid pain relief is unpredictable and rarely possible. After exhausting Western Medicine options, these women often turn to acupuncture. But in contrast to other pain conditions, there have been no acupuncture sham control studies of vulvodynia.
Only four studies, including one of the investigators', provide some evidence of the effect of acupuncture on vulvodynia. In three, single-group acupuncture studies, women had less pain, better quality of life, improved sexual health, and improved mental health. The investigators' randomized wait-list controlled pilot study of 36 women with vulvodynia showed great promise. The investigators found a statistically significant and clinically meaningful reduction in vulvar pain and dyspareunia, and an increase in overall sexual function after a 5-week, 13-needle, 10 session acupuncture protocol. This newly developed, standardized acupuncture treatment protocol is the first breakthrough in the treatment of this puzzling disorder. It includes acupuncture points that relieve pain in the genitals. The results of the investigators' initial pilot study provided the first evidence from a two-group design that the acupuncture protocol could reduce pain intensity, pain during intercourse, and increase overall sexual function. These findings, however, warrant stronger evidence to support the inference that the effect is indeed due to the acupuncture since ours or no other study included a sham control or provided follow-up data beyond immediate posttest, which means that the duration of the acupuncture effect is unknown. The investigators' recent feasibility study paves the way to overcome this gap by use of double-blind acupuncture needles. Findings from these two studies support the investigators' proposal for the world's first double-blind randomized controlled trial (RCT) of acupuncture for vulvodynia while exploring its duration of effect.
The investigators propose a phase 2 double-blind, pretest/posttest RCT to compare effects of penetrating needles or the skin touch placebo needles on vulvar pain in our 13-needle, 10-session acupuncture treatment protocol. A sample of 130 women, with a diagnosis of vulvodynia, either generalized or provoked vestibulodynia, 18 to 45 years of age will be recruited from clinical and community settings and 80 subjects are expected to complete the study. Stratified by type of vulvodynia, participants will be randomized 1:1 either to the penetrating needle group or the skin touch placebo needle group. These double-blind needles will provide a strong sham procedure to mask both the acupuncturist and subject to the type of needle used for the 10-treatment protocol.
Specific aims are to:
Aim 1. Compare the penetrating needle group and the skin touch placebo needle group for effects on the: (a) primary outcome: vulvar pain (PAINReportIt® average pain intensity, 0-10), and (b) secondary outcomes: dyspareunia (FSFI dyspareunia) and sexual function (FSFI total). The investigators hypothesize that controlling for baseline values, at posttest there will be statistically significant less vulvar pain (primary) and dyspareunia and better sexual function in the penetrating needle group compared to the skin touch placebo group.
Aim 2. In participants with a clinically meaningful reduction in pain intensity (at least 1.5 points) at posttest compared to pretest, describe the duration of the acupuncture treatment and placebo effects weekly until pain returns to pretest or up to 12 weeks after posttest. The investigators will describe the variability over time in vulvar pain intensity (0-10) after a tampon insertion-removal stimulus and thereby explore the duration of the effect by intervention group, vulvodynia subgroups, and demographic subgroups (e.g., age, race, occupation). These findings will provide insights to guide future research on initial and maintenance acupuncture for vulvodynia.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental: Active Acupuncture | Active Comparator | Active Acupuncture two times per week for 5 weeks |
|
| Placebo Acupuncture | Placebo Comparator | Placebo Acupuncture two times per week for 5 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active Acupuncture | Other | Active Acupuncture two times per week for 5 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Average Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS). | The subject calls the pain intensity a number ranging between the minimum value, 0 and 10, the maximum value. Zero represents "no pain" and 10 represents"pain as bad as it could be". Higher scores mean more pain. The PINS will include three items (pain now, least and worst pain in the past 24 hours), which are used to calculate the average of pain intensity. The PINS with the three items and standardized instructions is part of PAINReportIt® which is an electronic version of the 1970 version of the McGill Pain Questionnaire. | baseline and after the 10th acupuncture treatment week 5 |
| Measure | Description | Time Frame |
|---|---|---|
| Dyspareunia Subscale of the Female Sexual Function Index (FSFI) | The Dyspareunia Subscale of the FSFI measures pain with sexual intercourse. The FSFI consists of three items scored using a scale ranging from zero to five. The scores of the three items are then summed and multiplied by a factor of 0.4, resulting in a minimum score of 0 and a maximum score of 6.0, with higher scores indicating less pain with sexual intercourse. |
Not provided
Inclusion Criteria:
Exclusionary Criteria:
Patients may have a history of but not have active in the last 6 months migraine headaches, temporomandibular joint disease (TMJ), irritable bowel syndrome (IBS), interstitial cystitis, painful bladder syndrome, or fibromyalgia.
-
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Judith M. Schlaeger, PhD | University of Illinois at Chicago | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Illinois at Chicago College of Nursing | Chicago | Illinois | 60612 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36387991 | Derived | Schlaeger JM, Suarez ML, Glayzer JE, Kobak WH, Meinel M, Steffen AD, Burke LA, Pauls HA, Yao Y, Takayama M, Yajima H, Kaptchuk TJ, Takakura N, Foster D, Wilkie DJ. Protocol for double-blind RCT of acupuncture for vulvodynia. Contemp Clin Trials Commun. 2022 Nov 2;30:101029. doi: 10.1016/j.conctc.2022.101029. eCollection 2022 Dec. | |
| 36130137 |
Not provided
Not provided
The data generated by our research are available from the PI, Judith M. Schlaeger, upon reasonable request.
The data will be available immediately upon release of this ClinicalTrials.gov website for 5 years.
Please email the Principal Investigator: Judith Schlaeger, jschlaeg@uic.edu
Not provided
No participants were excluded after randomization and assignment to the groups.
Four-hundred and fifty women were assessed for eligibility of which 290 did not meet eligibility criteria and 71 declined to participate. Eighty-nine participants were enrolled between February 2018 and September 2022. Participants were recruited from community settings as well as from medical clinics throughout the Chicagoland area, from healthcare provider referrals, and from the National Vulvodynia Association website.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Experimental: Active Acupuncture | Active Acupuncture two times per week for 5 weeks Active Acupuncture: Active Acupuncture two times per week for 5 weeks |
| FG001 | Placebo Acupuncture | Placebo Acupuncture two times per week for 5 weeks Placebo Acupuncture: Placebo Acupuncture two times per week for 5 weeks |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
The analysis population is the same as the population in Participant Flow.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Experimental: Active Acupuncture | Active Acupuncture two times per week for 5 weeks Active Acupuncture: Active Acupuncture two times per week for 5 weeks |
| BG001 | Placebo Acupuncture |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Average Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS). | The subject calls the pain intensity a number ranging between the minimum value, 0 and 10, the maximum value. Zero represents "no pain" and 10 represents"pain as bad as it could be". Higher scores mean more pain. The PINS will include three items (pain now, least and worst pain in the past 24 hours), which are used to calculate the average of pain intensity. The PINS with the three items and standardized instructions is part of PAINReportIt® which is an electronic version of the 1970 version of the McGill Pain Questionnaire. | Participants receiving active acupuncture and placebo acupuncture | Posted | Mean | Standard Deviation | score on a scale | baseline and after the 10th acupuncture treatment week 5 |
|
The specific time period over which adverse event data were collected was 5 weeks, which started at the first acupuncture treatment and was completed after the 10th acupuncture treatment.
The definition of adverse events and serious adverse events does not differ from the clinicaltrials.gov definition.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Experimental: Active Acupuncture | Active Acupuncture two times per week for 5 weeks Active Acupuncture: Active Acupuncture two times per week for 5 weeks |
Not provided
Not provided
No limitations or caveats.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Judith M. Schlaeger, PhD, CNM, LAc, FAAN | University of Illinois Chicago | (312) 413-4469 | jschlaeg@uic.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 15, 2017 | Jan 20, 2025 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Feb 17, 2020 | Jan 20, 2025 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D056650 | Vulvodynia |
| D054515 | Vulvar Vestibulitis |
| D004414 | Dyspareunia |
| ID | Term |
|---|---|
| D014845 | Vulvar Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo Acupuncture | Other | Placebo Acupuncture two times per week for 5 weeks |
|
|
| baseline and after the 10th acupuncture treatment week 5 |
| Total Score of the Female Sexual Function Index (FSFI) | The FSFI is a 19-item, multi-dimensional, self-report measure that measures overall sexual function from six domains of sexual response: desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia. The six subscale scores are measured on a scale of 0-5 for each item. Individual item responses from each of the 6 domains are added together to achieve a domain score and are each multipled by a factor (desire, 0.6; arousal, 0.3; lubrication, 0.3; orgasm, 0.4; satisfaction, 0.4; and dyspareunia, 0.4). These final domain scores are summed to obtain the Total Score of the FSFI, ranging from 2.0 to 36.0, with higher scores indicating better overall sexual function. | baseline and after the 10th acupuncture treatment week 5 |
| Vulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS). | The subject calls the pain intensity a number between 0, the minimum value and 10, the maximum value. Zero is "no pain" and 10 is "pain as bad as it could be." Higher scores indicate a worse outcome. The PINS will include one item (vulvar pain intensity). The PINS with vulvar pain intensity and standardized instructions is part of PAINReportIt® which is an electronic version of the 1970 version of the McGill Pain Questionnaire. | after the 10th acupuncture treatment weekly up to 12 weeks post last acupuncture treatment. |
| Desloge AA, Patil CL, Glayzer JE, Suarez ML, Kobak WH, Meinel M, Steffen AD, Burke LA, Yao Y, Takayama M, Yajima H, Kaptchuk TJ, Takakura N, Foster DC, Wilkie DJ, Schlaeger JM. Women's Experience of Living with Vulvodynia Pain: Why They Participated in a Randomized Controlled Trial of Acupuncture. J Integr Complement Med. 2023 Jan;29(1):50-54. doi: 10.1089/jicm.2022.0647. Epub 2022 Sep 21. |
Placebo Acupuncture two times per week for 5 weeks
Placebo Acupuncture: Placebo Acupuncture two times per week for 5 weeks
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| OG001 | Placebo Acupuncture | Placebo Acupuncture two times per week for 5 weeks Placebo Acupuncture: Placebo Acupuncture two times per week for 5 weeks |
|
|
|
| Secondary | Dyspareunia Subscale of the Female Sexual Function Index (FSFI) | The Dyspareunia Subscale of the FSFI measures pain with sexual intercourse. The FSFI consists of three items scored using a scale ranging from zero to five. The scores of the three items are then summed and multiplied by a factor of 0.4, resulting in a minimum score of 0 and a maximum score of 6.0, with higher scores indicating less pain with sexual intercourse. | Participants receiving active acupuncture and placebo acupuncture. | Posted | Mean | Standard Deviation | score on a scale | baseline and after the 10th acupuncture treatment week 5 |
|
|
|
|
| Secondary | Total Score of the Female Sexual Function Index (FSFI) | The FSFI is a 19-item, multi-dimensional, self-report measure that measures overall sexual function from six domains of sexual response: desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia. The six subscale scores are measured on a scale of 0-5 for each item. Individual item responses from each of the 6 domains are added together to achieve a domain score and are each multipled by a factor (desire, 0.6; arousal, 0.3; lubrication, 0.3; orgasm, 0.4; satisfaction, 0.4; and dyspareunia, 0.4). These final domain scores are summed to obtain the Total Score of the FSFI, ranging from 2.0 to 36.0, with higher scores indicating better overall sexual function. | Participants receiving active acupuncture and placebo acupuncture. | Posted | Mean | Standard Deviation | score on a scale | baseline and after the 10th acupuncture treatment week 5 |
|
|
|
|
| Secondary | Vulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS). | The subject calls the pain intensity a number between 0, the minimum value and 10, the maximum value. Zero is "no pain" and 10 is "pain as bad as it could be." Higher scores indicate a worse outcome. The PINS will include one item (vulvar pain intensity). The PINS with vulvar pain intensity and standardized instructions is part of PAINReportIt® which is an electronic version of the 1970 version of the McGill Pain Questionnaire. | Participants receiving active acupuncture and placebo acupuncture that entered the Duration of Effect phase. Participants with a clinically meaningful reduction in pain intensity (at least 1.5 points) at the 10th acupuncture treatment compared to pretest, will measure Vulvar Pain Intensity weekly until pain returns to pretest or up to 12 weeks after the 10th acupuncture treatment. | Posted | Mean | Standard Deviation | score on a scale | after the 10th acupuncture treatment weekly up to 12 weeks post last acupuncture treatment. |
|
|
|
|
| 0 |
| 45 |
| 0 |
| 45 |
| 0 |
| 45 |
| EG001 | Placebo Acupuncture | Placebo Acupuncture two times per week for 5 weeks Placebo Acupuncture: Placebo Acupuncture two times per week for 5 weeks | 0 | 44 | 0 | 44 | 0 | 44 |
Not provided
Not provided
Not provided
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D014847 | Vulvitis |
| D005832 | Genital Diseases, Male |
| D012735 | Sexual Dysfunction, Physiological |
| D052801 | Male Urogenital Diseases |
| D020018 | Sexual Dysfunctions, Psychological |
| D001523 | Mental Disorders |
| Week 2 |
|
|
| Week 3 |
|
|
| Week 4 |
|
|
| Week 5 |
|
|
| Week 6 |
|
|
| Week 7 |
|
|
| Week 8 |
|
|
| Week 9 |
|
|
| Week 10 |
|
|
| Week 11 |
|
|
| Week 12 |
|
|